Clinical trials: Human Papillomavirus Vaccines
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients
This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period…
- Trial name
- NCT03036930
- Testing
- Biospecimen Collection, HPV Self-Collection, Questionnaire Administration
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Human Papillomavirus Infection
Comparative Effectiveness of System Interventions to Increase HPV Vaccine Receipt in FQHCs
UCLA and Northeast Valley Health Center (NEVHC), a large, multi-site Federally Qualified Health Center (FQHC), are partnering to address underutilization of the prophylactic HPV vaccine among underserved, ethnic minority…
- Trial name
- NCT03726151
- Testing
- Parent Reminders, Multicomponent clinic-system strategies, Combined Condition
- Where
- 7 sites in United States
- Volunteers
- 17,000 people
- Sponsor
- University of California, Los Angeles
Transplant
Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients
Human papillomavirus (HPV) affects a significant number of transplant patients. In women, human papillomavirus (HPV) causes genital warts, pre-cancerous areas of the cervix, and cervical cancer.
- Trial name
- NCT00677677
- Testing
- Human papillomavirus quadrivalent vaccine
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- University of Alberta
Vaccine Refusal
An Online Intervention Promoting HPV Vaccination Among Chinese MSM
Hong Kong Chinese speaking men who have sex with men completed a baseline survey, and then received an online intervention promoting uptake of Human Papillomavirus (HPV) vaccination.
- Trial name
- NCT04815837
- Testing
- Intervention
- Where
- Hong Kong
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Chinese University of Hong Kong
Infections, Papillomavirus, Papillomavirus Vaccines
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age
HPV infection has been established as a necessary cause of cervical cancer. GSK Biologicals has developed an HPV-16/18 L1 VLP AS04 vaccine (Cervarix TM) which targets the 2 most common oncogenic HPV types (HPV-16 and HPV-18)…
- Trial name
- NCT00423046
- Testing
- GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM), Gardasil ® (Merck & Co. Inc)
- Where
- 40 sites in United States
- Volunteers
- 1,106 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Vaccine Refusal
Optimizing HPV Vaccine Introduction in Shanghai, China
Within low, middle, and upper income countries, low vaccine coverage results from both obstacles to vaccine access and low confidence in vaccine programs.
- Trial name
- NCT03972813
- Testing
- Broadened information about cancers, Information about STDs, Information about infectious disease
- Where
- China
- Volunteers
- 1,021 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Infections, Papillomavirus
Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus…
- Trial name
- NCT00231413
- Testing
- HPV 16/18 L1 AS04, HPV-16/18/31/45 L1 AS04 Formulation 1, HPV-16/18/31/45 L1 AS04 Formulation 2
- Where
- 11 sites in United States, Belgium
- Volunteers
- 383 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Papillomavirus Viruses, Papillomavirus Vaccines
Let's K-Talk - HPV Study for Ethnic Koreans
The goal of this clinical trial is to test the feasibility, acceptability, and preliminary efficacy of a storytelling video-based intervention using AI chatbot technology (K-Talk) to promote HPV vaccination behavior among Korean…
- Trial name
- NCT05884697
- Testing
- K-Talk Intervention (Storytelling and K-Bot), Storytelling Intervention, K-Bot Intervention
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Cincinnati
HPV Infection, Preventive Health Services
PCOM2 - The Physician Communication Intervention, Version 2.0
Poor quality of primary care providers' vaccine recommendations lead to low adolescent human papillomavirus vaccination rates and hundreds of thousands of adolescents unnecessarily at risk for HPV-associated cancers and diseases.
- Trial name
- PCOM2 (NCT05336240)
- Testing
- Physician Communication 2 Virtual (PCOM2-virtual), Physician Communication Standard (PCOM-standard)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- University of Colorado, Denver
HPV Vaccination, Uptake Vaccination
PREVENT Pilot HPV - Related Cancers Trial
This study will serve as one of the first to develop and test the effectiveness of strategies to promote HPV vaccination among diverse rural parents and caregivers of children ages 9-17 years in the Mountain West.
- Conditions
- HPV Vaccination, Uptake Vaccination, Series Completion
- Trial name
- NCT06738355
- Testing
- PREVENT
- Where
- United States
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- University of Utah
Cervical Cancer, Human Papillomavirus Infection
Effect of Health Belief Model-Based Education on Cervical Cancer Knowledge and HPV Vaccine Attitudes in Women
This study evaluated the effect of a Health Belief Model-based educational intervention on women's knowledge of cervical cancer and their attitudes and beliefs toward HPV vaccination.
- Conditions
- Cervical Cancer, Human Papillomavirus Infection, Preventive Health Services
- Trial name
- HBM-HPV (NCT07521163)
- Testing
- Health Belief Model-Based Education
- Where
- Turkey (Türkiye)
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Muhammet Faruk Yigit
Systemic Lupus Erythematosus
Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women
The purpose of this study is to evaluate the immunogenicity and safety of the HPV vaccine Gardasil in young women.
- Trial name
- NCT00786409
- Testing
- Gardasil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Chicago
Human Papillomavirus Vaccination
Investigating HPV Vaccination Uptake in Adults Aged 18-35 Seeking Care at a Health Clinic in Rural Mississippi
A study evaluating HPV vaccine uptake among unvaccinated patients between the ages of 18 and 35 of a mobile health clinic serving the Mississippi Delta.
- Trial name
- NCT05658198
- Testing
- Counseling
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Plan A Health, Inc
Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer
Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)
70% all cases of cervical cancer, 95% of anal cancers and about 70% of oropharyngeal cancers are linked to Human Papillomavirus (HPV) infection. HPV oncogenic proteins are trans-activators of telomerase.
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Anal Canal Cancer, Cervical Cancer
- Trial name
- VolATIL (NCT03946358)
- Testing
- Blood sample collection, Tumor biopsies, CT scan
- Where
- 4 sites in France
- Volunteers
- 47 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Human Papilloma Virus (HPV) Vaccine
HPV Multilevel Intervention Strategies Targeting Immunization in Community Settings (HPV MISTICS)
This intervention study will use parent-, provider-, and health center-level strategies to promote HPV vaccination among 11-17 year olds receiving care in 8 community health centers in Florida, will explore factors related to the…
- Trial name
- HPV MISTICS (NCT05677360)
- Testing
- HPV MISTICS -Provider Level, HPV MISTICS - Parent Level, HPV MISTICS- HPV Vaccine Champion Level
- Where
- United States
- Volunteers
- 148 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Infections, Papillomavirus
Evaluation of Safety of a Vaccine Against Cervical Cancer in Healthy Korean Females
This Post Marketing Surveillance (PMS) will collect safety data on the use of GSK Biologicals' human papillomavirus (HPV) vaccine in the local target population of females as per the regulations of the Korean Food and Drugs…
- Trial name
- NCT01101542
- Testing
- Cervarix., Data collection
- Where
- 2 sites in South Korea
- Volunteers
- 3,091 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cervical Cancer
Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions
Cervical cancer is the most frequent neoplasm and the third in mortality rate of the malignancies in women in the world. It results in about 200,000 women dying of cervical cancer each year worldwide.
- Trial name
- NCT00154583
- Where
- Taiwan
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Human Papillomavirus, High-Grade Squamous Intraepithelial Lesions
Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL
The purpose of this research study is to test the safety and effectiveness of the investigational study vaccine, called TVGV-1. The study will test the vaccine in women with high grade HPV cervical infection.
- Trial name
- NCT02576561
- Testing
- TVGV-1, GPI-0100
- Where
- 11 sites in United States
- Volunteers
- 10 people
- Sponsor
- THEVAX Genetics Vaccine
Healthy Adult Female Participants, Prevention
A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)
This study was conducted to assess the safety, immunogenicity, efficacy and long-term effectiveness of a vaccine being evaluated for the prevention of human papillomavirus (HPV) infection and disease in mid-adult women.
- Conditions
- Healthy Adult Female Participants, Prevention, Papillomavirus Infection, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
- Trial name
- NCT00090220
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine
- Volunteers
- 3,819 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II
HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia
The primary goal of this phase I open label study is to determine the safety and tolerability of pNGVL4aCRTE6E7L2 DNA vaccine, as administered by intramuscular (IM) injection with TriGrid™ electroporation to both HIV- or HIV+…
- Conditions
- Human Papillomavirus Type 16, Cervical Intraepithelial Neoplasia Grade II, Cervical Intraepithelial Neoplasia, Grade III
- Trial name
- NCT04131413
- Testing
- pNGVL4aCRTE6E7L2
- Where
- 2 sites in United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins